2026-09-18T23:37:34Zhttps://dspace.mit.edu/server/oai/requestoai:dspace.mit.edu:1721.1/478652022-01-13T07:55:19Zcom_1721.1_7582com_1721.1_7581col_1721.1_131023
Fiona Murray and Eric A. von Hippel.
Bharadwaj, Ragu
System Design and Management Program.
System Design and Management Program.
2009-10-01T15:55:20Z
2009-10-01T15:55:20Z
2009
2009
http://hdl.handle.net/1721.1/47865
432329740
Thesis (S.M.)--Massachusetts Institute of Technology, System Design and Management Program, 2009.
Includes bibliographical references (leaves 57-59).
The pharmaceutical industry needs new modes of innovation. The industry's innovation system - based on massive investments in R&D protected by intellectual property rights - has worked well for many years, providing incentives for pharmaceutical firms to invest in developing drugs across a wide variety of major medical needs. However, this traditional drug development process is subject to decreasing productivity and increasing costs. In addition, it encourages pharmaceutical firms to focus on "blockbuster" drugs, and to neglect meeting needs in small potential markets such as "orphan" diseases and diseases primarily found in third world countries. This thesis focuses on new modes of innovation, specifically the sharing of safety information prior to clinical trials. To inform this analysis, I first discuss the data that informs why the industry is in need of new modes of innovation. I then proceed to outline the potential promise of some new modes of pharmaceutical development that are emerging. I then explore a specific novel innovation mode in more detail: the sharing of non-competitive safety information prior to clinical trials, leading to significant reductions in both costs and chances of failure in drug discovery and development. I propose that this new innovation mode offers the potential of significant benefit to both drug developers and medical patients.
by Ragu Bharadwaj.
S.M.
59 leaves
eng
Massachusetts Institute of Technology
M.I.T. theses are protected by
copyright. They may be viewed from this source for any purpose, but
reproduction or distribution in any format is prohibited without written
permission. See provided URL for inquiries about permission.
http://dspace.mit.edu/handle/1721.1/7582
System Design and Management Program.
Business models for information commons in the pharmaceutical industry
Thesis
application/pdf
Publication
unknown
unknown
<Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="5151978e-19d8-4caf-8574-f7cd1f23f271">
<Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type>
<Language>eng</Language>
<Title>Business models for information commons in the pharmaceutical industry</Title>
<PublishedIn>
<Publication>
</Publication>
</PublishedIn>
<PublicationDate>2009</PublicationDate>
<Authors>
<Author>
<DisplayName>Bharadwaj, Ragu</DisplayName>
<Affiliation>
<OrgUnit>
</OrgUnit>
</Affiliation>
</Author>
</Authors>
<Editors>
</Editors>
<Publishers>
<Publisher>
<DisplayName>Massachusetts Institute of Technology</DisplayName>
<OrgUnit />
</Publisher>
</Publishers>
<License>http://dspace.mit.edu/handle/1721.1/7582</License>
<Keyword>System Design and Management Program.</Keyword>
<Abstract>The pharmaceutical industry needs new modes of innovation. The industry's innovation system - based on massive investments in R&D protected by intellectual property rights - has worked well for many years, providing incentives for pharmaceutical firms to invest in developing drugs across a wide variety of major medical needs. However, this traditional drug development process is subject to decreasing productivity and increasing costs. In addition, it encourages pharmaceutical firms to focus on "blockbuster" drugs, and to neglect meeting needs in small potential markets such as "orphan" diseases and diseases primarily found in third world countries. This thesis focuses on new modes of innovation, specifically the sharing of safety information prior to clinical trials. To inform this analysis, I first discuss the data that informs why the industry is in need of new modes of innovation. I then proceed to outline the potential promise of some new modes of pharmaceutical development that are emerging. I then explore a specific novel innovation mode in more detail: the sharing of non-competitive safety information prior to clinical trials, leading to significant reductions in both costs and chances of failure in drug discovery and development. I propose that this new innovation mode offers the potential of significant benefit to both drug developers and medical patients.</Abstract>
<Access xmlns="http://purl.org/coar/access_right"
>
</Access>
</Publication>